Insulin action on heart and skeletal muscle glucose uptake in essential hypertension. 1995

P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
Department of Medicine, Turku University Cyclotron/PET Center, University of Turku, Finland.

Essential hypertension is characterized by skeletal muscle insulin resistance but it is unknown whether insulin resistance also affects heart glucose uptake. We quantitated whole body (euglycemic insulin clamp) and heart and skeletal muscle (positron emission tomography and 18F-fluoro-2-deoxy-D-glucose) glucose uptake rates in 10 mild essential hypertensive (age 33 +/- 1 yr, body mass index 23.7 +/- 0.8 kg/m2, blood pressure 146 +/- 3/97 +/- 3 mmHg, VO2max 37 +/- 3 ml/kg per min) and 14 normal subjects (29 +/- 2 yr, 22.5 +/- 0.5 kg/m2, 118 +/- 4/69 +/- 3 mmHg, 43 +/- 2 ml/kg per min). Left ventricular mass was similar in the hypertensive (155 +/- 15 g) and the normotensive (164 +/- 13 g) subjects. In the hypertensives, both whole body (28 +/- 3 vs 44 +/- 3 mumol/kg per min, P < 0.01) and femoral (64 +/- 11 vs 94 +/- 8 mumol/kg muscle per min, P < 0.05) glucose uptake rates were decreased compared to the controls. In contrast, heart glucose uptake was 33% increased in the hypertensives (939 +/- 51 vs 707 +/- 46 mumol/kg muscle per min, P < 0.005), and correlated with systolic blood pressure (r = 0.66, P < 0.001) and the minute work index (r = 0.48, P < 0.05). We conclude that insulin-stimulated glucose uptake is decreased in skeletal muscle but increased in proportion to cardiac work in essential hypertension. The increase in heart glucose uptake in mild essential hypertensives with a normal left ventricular mass may reflect increased oxygen consumption and represent an early signal which precedes the development of left ventricular hypertrophy.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007091 Image Processing, Computer-Assisted A technique of inputting two-dimensional or three-dimensional images into a computer and then enhancing or analyzing the imagery into a form that is more useful to the human observer. Biomedical Image Processing,Computer-Assisted Image Processing,Digital Image Processing,Image Analysis, Computer-Assisted,Image Reconstruction,Medical Image Processing,Analysis, Computer-Assisted Image,Computer-Assisted Image Analysis,Computer Assisted Image Analysis,Computer Assisted Image Processing,Computer-Assisted Image Analyses,Image Analyses, Computer-Assisted,Image Analysis, Computer Assisted,Image Processing, Biomedical,Image Processing, Computer Assisted,Image Processing, Digital,Image Processing, Medical,Image Processings, Medical,Image Reconstructions,Medical Image Processings,Processing, Biomedical Image,Processing, Digital Image,Processing, Medical Image,Processings, Digital Image,Processings, Medical Image,Reconstruction, Image,Reconstructions, Image
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D003847 Deoxyglucose 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity. 2-Deoxy-D-glucose,2-Deoxyglucose,2-Desoxy-D-glucose,2 Deoxy D glucose,2 Deoxyglucose,2 Desoxy D glucose
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose

Related Publications

P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
February 1991, Hypertension (Dallas, Tex. : 1979),
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
April 1999, The American journal of physiology,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
July 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
August 1978, FEBS letters,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
April 2016, Hormone molecular biology and clinical investigation,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
March 1992, Metabolism: clinical and experimental,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
September 1978, Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
January 1975, The Biochemical journal,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
June 1988, The Biochemical journal,
P Nuutila, and M Mäki, and H Laine, and M J Knuuti, and U Ruotsalainen, and M Luotolahti, and M Haaparanta, and O Solin, and A Jula, and V A Koivisto
July 2020, Comprehensive Physiology,
Copied contents to your clipboard!